HC Wainwright Issues Positive Outlook for ALDX Earnings

Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) - Research analysts at HC Wainwright lifted their Q2 2025 earnings per share estimates for shares of Aldeyra Therapeutics in a report issued on Monday, May 19th. HC Wainwright analyst M. Caufield now forecasts that the biotechnology company will earn ($0.18) per share for the quarter, up from their previous estimate of ($0.26). HC Wainwright currently has a "Buy" rating and a $10.00 target price on the stock. The consensus estimate for Aldeyra Therapeutics' current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for Aldeyra Therapeutics' Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.54) EPS, FY2026 earnings at ($0.26) EPS, FY2027 earnings at $0.26 EPS and FY2028 earnings at $0.64 EPS.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last issued its earnings results on Wednesday, May 14th. The biotechnology company reported ($0.17) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.08.

Several other equities analysts also recently weighed in on ALDX. BTIG Research decreased their target price on Aldeyra Therapeutics from $11.00 to $9.00 and set a "buy" rating on the stock in a research report on Monday, April 7th. Wall Street Zen upgraded shares of Aldeyra Therapeutics to a "sell" rating in a research report on Wednesday, May 21st.

Aldeyra Therapeutics Price Performance

NASDAQ ALDX traded down $0.03 on Wednesday, hitting $2.22. The company had a trading volume of 704,068 shares, compared to its average volume of 790,462. The company has a market capitalization of $132.97 million, a PE ratio of -2.29 and a beta of 0.92. Aldeyra Therapeutics has a 12-month low of $1.14 and a 12-month high of $7.20. The company's fifty day moving average price is $3.12 and its 200-day moving average price is $4.62. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.80 and a quick ratio of 6.80.

Institutional Trading of Aldeyra Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC raised its position in shares of Aldeyra Therapeutics by 14.4% during the 4th quarter. SG Americas Securities LLC now owns 22,365 shares of the biotechnology company's stock worth $112,000 after acquiring an additional 2,822 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Aldeyra Therapeutics by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 1,119,555 shares of the biotechnology company's stock valued at $5,588,000 after buying an additional 4,927 shares in the last quarter. Wells Fargo & Company MN grew its position in shares of Aldeyra Therapeutics by 1.9% in the 4th quarter. Wells Fargo & Company MN now owns 393,654 shares of the biotechnology company's stock valued at $1,964,000 after buying an additional 7,348 shares during the last quarter. Intech Investment Management LLC grew its position in shares of Aldeyra Therapeutics by 62.7% in the 4th quarter. Intech Investment Management LLC now owns 23,806 shares of the biotechnology company's stock valued at $119,000 after buying an additional 9,178 shares during the last quarter. Finally, Barclays PLC raised its stake in Aldeyra Therapeutics by 14.9% during the 4th quarter. Barclays PLC now owns 75,330 shares of the biotechnology company's stock worth $376,000 after acquiring an additional 9,769 shares in the last quarter. 59.71% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Aldeyra Therapeutics

In related news, major shareholder Perceptive Advisors Llc sold 3,400,000 shares of the business's stock in a transaction on Thursday, April 3rd. The shares were sold at an average price of $1.42, for a total transaction of $4,828,000.00. Following the completion of the transaction, the insider now owns 5,875,851 shares in the company, valued at approximately $8,343,708.42. The trade was a 36.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 9.60% of the stock is currently owned by corporate insiders.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.